Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart Failure RTT News Acorda Therapeutics Inc. (ACOR: Quote) today announced that the first patient has been enrolled in the second trial of Glial Growth Factor 2 or GGF2. This Phase 1b single-infusion study in people with heart failure would evaluate tolerability of three ... |
